J. CRAIG VENTER INSTITUTE, INC.

J. Craig Venter Institute, Inc. specializes in advanced genomic research and high-throughput biological testing services, with deep expertise in synthetic biology, genetic sequencing, and rapid molecular construct development. The contractor delivers end-to-end solutions for plasmid synthesis, mutagenesis, and genomic analysis of complex biological samples, including wound microbiomes and pathogenic strains. Their technical capabilities center on omics infrastructure, next-generation sequencing platforms, and bioinformatics pipelines designed for precision biological discovery. A key differentiator is their ability to rapidly engineer and validate genetic constructs under stringent regulatory and operational constraints, enabling agile responses to emerging public health and defense threats. The organization maintains a strong track record with the Department of Health and Human Services and the Department of Defense, providing mission-critical biotechnology services to both civilian and military agencies. For HHS, they operate centralized omics resource cores that support large-scale genomic data generation and analysis. For the DoD, they execute high-priority research initiatives in biodefense and battlefield medicine, including sequencing of wound-associated microbial communities and development of synthetic biology tools for rapid diagnostic and therapeutic deployment. Their primary industry focus lies in testing laboratories and services (541380) and biotechnology R&D (541714), where they bridge fundamental science with applied operational needs. They are positioned as a specialized provider for complex life science challenges requiring molecular precision, automation, and scalable bioinformatics, serving federal agencies engaged in biodefense, infectious disease surveillance, and personalized medical countermeasures. As a non-certified entity based in La Jolla, California, the institute operates as an independent research contractor with a focused, science-driven business model. Their geographic presence in a major biotech hub enhances access to academic partnerships and advanced instrumentation, reinforcing their role as a high-impact, mission-aligned provider in the federal life sciences market.